Hepatic encephalopathy: An update of pathophysiologic mechanisms

被引:230
作者
Hazell, AS [1 ]
Butterworth, RF [1 ]
机构
[1] Univ Montreal, Ctr Hosp, Neurosci Res Unit, Montreal, PQ H2X 3J4, Canada
来源
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE | 1999年 / 222卷 / 02期
关键词
D O I
10.1046/j.1525-1373.1999.d01-120.x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hepatic encephalopathy (HE) is a neuropsychiatric disorder that occurs in both acute and chronic liver failure. Although the precise pathophysiologic mechanisms responsible for HE are not completely understood, a deficit in neurotransmission rather than a primary deficit in cerebral energy metabolism appears to be involved. The neural cell most vulnerable to liver failure is the astrocyte, In acute liver failure, the astrocyte undergoes swelling resulting in increased intracranial pressure; in chronic liver failure, the astrocyte undergoes characteristic changes known as Alzheimer type II astrocytosis. In portal-systemic encephalopathy resulting from chronic liver failure, astrocytes manifest altered expression of several key proteins and enzymes including monoamine oxidase B, glutamine synthetase, and the so-called peripheral-type benzodiazepine receptors, In addition, expression of some neuroneal proteins such as monoamine oxidase A and neuronal nitric oxide synthase are modified. In acute liver failure, expression of the astrocytic glutamate transporter GLT-1 is reduced, leading to increased extracellular concentrations of glutamate, Many of these changes have been attributed to a toxic effect of ammonia and/or manganese, two substances that are normally removed by the hepatobiliary route and that in liver failure accumulate in the brain. Manganese deposition in the globus pallidus in chronic liver failure results in signal hyperintensity on T1-weighted Magnetic Resonance Imaging and may be responsible for the extrapyramidal symptoms characteristic of portal-systemic encephalopathy, Other neurotransmitter systems implicated in the pathogenesis of hepatic encephalopathy include the serotonin system, where a synaptic deficit has been suggested, as well as the catecholaminergic and opioid systems. Further elucidation of the precise nature of these alterations could result in the design of novel pharmacotherapies for the prevention and treatment of hepatic encephalopathy.
引用
收藏
页码:99 / 112
页数:14
相关论文
共 160 条
[1]   ACTIVATION OF ARGININE METABOLISM TO GLUTAMATE IN RAT-BRAIN SYNAPTOSOMES IN THIOACETAMIDE-INDUCED HEPATIC-ENCEPHALOPATHY - AN ADAPTATIVE RESPONSE [J].
ALBRECHT, J ;
HILGIER, W ;
RAFALOWSKA, U .
JOURNAL OF NEUROSCIENCE RESEARCH, 1990, 25 (01) :125-130
[2]   A PROPOSED THERAPY FOR THE ENCEPHALOPATHIES OF REYES-SYNDROME AND HEPATIC-ENCEPHALOPATHY [J].
ANDERSON, B .
MEDICAL HYPOTHESES, 1984, 15 (04) :415-420
[3]  
[Anonymous], 1981, ADV CELL NEUROBIOL
[4]  
Apelqvist G, 1998, ACTA PHYSIOL SCAND, V162, P509
[5]   MANGANESE UPTAKE AND EFFLUX IN CULTURED RAT ASTROCYTES [J].
ASCHNER, M ;
GANNON, M ;
KIMELBERG, HK .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (02) :730-735
[6]   Portacaval anastomosis results in more widespread alterations of cerebral metabolism in old versus young adult rats: Implications for post-shunt encephalopathy [J].
Audet, RM ;
Butterworth, RF .
METABOLIC BRAIN DISEASE, 1998, 13 (01) :69-78
[7]   GABAA RECEPTOR COMPLEX IN AN EXPERIMENTAL-MODEL OF HEPATIC-ENCEPHALOPATHY - EVIDENCE FOR ELEVATED LEVELS OF AN ENDOGENOUS BENZODIAZEPINE RECEPTOR LIGAND [J].
BASILE, AS ;
GAMMAL, SH ;
JONES, EA ;
SKOLNICK, P .
JOURNAL OF NEUROCHEMISTRY, 1989, 53 (04) :1057-1063
[8]  
BASILE AS, 1991, PHARMACOL REV, V43, P27
[9]   OBSERVATION OF CEREBRAL METABOLITES IN AN ANIMAL-MODEL OF ACUTE LIVER-FAILURE INVIVO - A H-1 AND P-31 NUCLEAR MAGNETIC-RESONANCE STUDY [J].
BATES, TE ;
WILLIAMS, SR ;
KAUPPINEN, RA ;
GADIAN, DG .
JOURNAL OF NEUROCHEMISTRY, 1989, 53 (01) :102-110
[10]   Effects of ammonia on L-glutamate uptake in cultured astrocytes [J].
Bender, AS ;
Norenberg, MD .
NEUROCHEMICAL RESEARCH, 1996, 21 (05) :567-573